carbostyril has been researched along with Body Weight in 89 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (5.62) | 18.7374 |
1990's | 16 (17.98) | 18.2507 |
2000's | 34 (38.20) | 29.6817 |
2010's | 29 (32.58) | 24.3611 |
2020's | 5 (5.62) | 2.80 |
Authors | Studies |
---|---|
Begnel, L; Litvin, M; Petersen, MC; Wallendorf, M | 1 |
Coppes, RP; Du, L; Gao, S; Li, F; Li, K; Liu, F; Luo, Y; Pan, Y; Yao, Z; Zhang, D; Zhang, H; Zhu, J | 1 |
Eriksson, H; Meehan, SR; Newcomer, JW; Weiss, C; Zhang, P | 1 |
Guimbellot, JS; Heltshe, SL; Jain, M; Jovanovic, B; Rowe, SM; Sagel, SD; Secunda, KE | 1 |
Chen, N; Feng, M; Guo, B; Huang, J; Li, X; Lin, D; Zhao, X; Zou, J | 1 |
Che, KK; Hu, CH; Li, DJ; Liu, L; Liu, XM; Yue, Q | 1 |
Blusch, A; Brunner, J; Ellrichmann, G; Fatoba, O; Gold, R; Hayardeny, L; Hayden, M; Reick, C; Saft, C; Sehr, D; Winklhofer, KF | 1 |
Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J | 1 |
Benchitrit, J; Drüeke, TB; Edelman, A; Galmiche, A; Guerrera, IC; Guillonneau, F; Ivanovski, O; Joki, N; Lacour, B; Lucas, A; Maizel, J; Marçon, F; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG; Phan, O | 1 |
Berk, M; Ghanizadeh, A; Sahraeizadeh, A | 1 |
Forbes, RA; Mankoski, R; Manos, G; Marcus, R; Marler, S; McQuade, R; Stockton, G | 1 |
Singh, KP; Tripathi, N | 1 |
Barry, PJ; Horsley, AR; Jones, AM; Webb, AK | 1 |
Buchanan, RW; Newcomer, JW; Weiden, PJ | 1 |
Liu, J; Meng, X; Xia, SY; Yu, H; Zhang, P; Zhang, YR | 1 |
Chen, QK; Lai, Y; Li, JY; Ouyang, H; Shan, TD; Xia, ZS; Yang, HS; Yu, T; Zhong, W | 1 |
Blier, P; Bundgaard, C; El Mansari, M; Oosterhof, CA | 1 |
Anamthathmakula, P; Sahu, A; Sahu, M | 1 |
Davis, J; Heltshe, SL; Higgins, MN; Niknian, M; Pace, J; Rowe, SM; Stalvey, MS; Tarn, V | 1 |
Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A | 1 |
Burnett, K; Chang, WY; Chen, Y; Griffiths, KN; Hogue, A; López, FJ; Mais, DE; Marschke, K; Meglasson, MD; Pedram, B; Shen, Y; Vajda, EG; van Oeveren, A; Zhi, L | 1 |
Terao, T | 1 |
Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R | 1 |
Bria, P; Janiri, L; Mazza, M; Pecora, RD; Squillacioti, MR | 1 |
Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY | 1 |
Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H | 1 |
Gebicke-Härter, PJ; Schmitt, A; Segnitz, N; Zink, M | 1 |
Englisch, S; Inta, D; Weinbrenner, A; Zink, M | 1 |
Kashima, H; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 1 |
Coffey, BJ; Goldman, R; Hirsch, S; Jummani, R; Lyon, GJ; Samar, S; Spirgel, A | 1 |
Hahn, SW; Ham, BJ; Kang, RH; Lee, HY; Lee, MS; Paik, JW | 1 |
Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP | 1 |
Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
Lee, SY; Pae, CU; Park, MH; Patkar, AA | 1 |
Cohn, T; Faulkner, G; Mukundan, A; Remington, G | 1 |
Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D | 1 |
Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
Berge, RK; Diéguez, C; Fernø, J; Fjær, S; López, M; Lunder, N; Pavlin, T; Skrede, S; Steen, VM; Vázquez, MJ; Vidal-Puig, A | 1 |
Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
Bowden, CL; Carlson, BX; Eudicone, JM; Marcus, R; McQuade, RD; Nashat, M; Thase, ME | 1 |
Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP | 1 |
Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z | 1 |
Elsheikh, HA; Khalafallah, AI; Osman, IA; Taha, AA | 1 |
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
Glisson, JR; Hofacre, CL; Mathis, GF | 1 |
Brøsen, K; Frimodt-Møller, N; Gahrn-Hansen, B; Madsen, H | 1 |
Britt, CS; Daniels, AJ; Grizzle, MK; Ignar, DM; Jones, DN; Kalinichev, M; Rourke, C | 1 |
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
Abou-Gharbia, N; Bourin, M; Carson, W; Iwamoto, T; Marcus, R; McQuade, R; Sanchez, R; Stock, E; Swanink, R; Vieta, E | 1 |
Abou-Gharbia, N; Carson, W; Impellizzeri, C; Iwamoto, T; Kaplita, S; Marcus, R; McQuade, R; Rollin, L; Sachs, G; Sanchez, R; Stock, E | 1 |
Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD | 1 |
Aisaka, K; Kuraishi, Y; Maekawa, T; Nojima, H | 1 |
Duane, DD | 1 |
Harborne, GC; Karunakaran, K; Tungaraza, TE | 1 |
Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A | 1 |
Altshuler, LL; Frye, MA; Keck, PE; Leverich, GS; Martens, B; McElroy, SL; Post, RM; Stanford, K; Suppes, T | 1 |
Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD | 1 |
Haug, SR; Heyeraas, KJ; Ibrahim, SO; Raju, B | 1 |
Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD | 1 |
Bai, DS; Sea, HS; Seo, WS; Sung, HM | 1 |
Heath, H; Poulsom, R | 1 |
Aldred, KL; Burrell, LM; Hutchins, AM; Johnston, CI; Phillips, PA; Risvanis, J | 1 |
Kanno, Y; Okada, H; Saruta, T; Suzuki, H | 2 |
Arakawa, K; Ichihara, A; Matsumoto, A; Murakami, M; Naitoh, M; Nakamoto, H; Oka, K; Saruta, T; Suzuki, H; Yamamura, Y | 1 |
Branstetter, DG; Hampton, LA; Linseman, DA | 1 |
Creveld, CV; Gavrielli, R; Glickman, A; Yagil, R; Ziv, G | 1 |
Ishibashi, S; Iwakura, K; Kawaminami, A; Shindo, Y; Sumi, N; Tawaratani, T; Uchimoto, H; Yoshida, M | 1 |
Kato, M; Miyamoto, M; Nomura, M; Shimoda, K; Sugawara, T; Takada, S; Yoshida, M | 1 |
Hamaguchi, A; Iwao, H; Kato, Y; Kim, S; Miura, K; Ohta, K; Shinkawa, T; Tsuchiya, N | 1 |
Brumbaugh, GW; Lizarraga, RE; Ocampo, CL; Sumano, LH | 1 |
Hashimoto, M; Makino, H; Mimura, Y; Ogura, T; Oishi, T; Otsuka, F; Yamauchi, T | 1 |
Hasimoto, K; Itoh, N; Owen, K; Takizawa, T; Yamashita, S | 1 |
Iki, K; Kido, A; Konishi, Y; Morishita, T; Motoyama, M; Takahama, M; Tamai, S; Tatsumi, K; Tsujiuchi, T; Tsutsumi, M | 1 |
Gunnarsson, A; Pedersen Mörner, A; Segall, T; Wallgren, P | 1 |
Carlotti, DN; Guaguere, E; Guiral, V; Jasmin, P; Pin, D; Thomas, E | 1 |
Aramayona, JJ; Bregante, MA; Fraile, L; Garcia, MA; Saez, P; Solans, C | 1 |
Honjo, S; Kawabata, K; Kohno, H; Murakami, M; Ota, T; Tanaka, T; Tsuda, H | 1 |
Chung, MK; Han, SS; Kim, JC; Shin, HC; Yun, HI | 1 |
Burrell, LM; Fraser, TB; Li, M; Turner, SW; Wen, C; Whitworth, JA | 1 |
Kyriakis, SC; Sarris, K; Tsiloyiannis, VK; Vlemmas, J | 1 |
Gupta, S; Huan, JN; Pal, R; Sahu, A; Zhao, AZ | 1 |
Art, T; Lekeux, P | 1 |
Higgins, C; McAnulty, PA; Tesh, JM; Tesh, SA; Wilby, OK; Willoughby, CR | 2 |
McAnulty, PA; Tesh, JM; Tesh, SA; Wilby, OK; Willoughby, CR | 1 |
4 review(s) available for carbostyril and Body Weight
Article | Year |
---|---|
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2013 |
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain | 2010 |
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2012 |
[Antibiotics and overweight].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Body Weight; Cephalosporins; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Humans; Obesity; Penicillins; Quinolones; Vancomycin | 2005 |
28 trial(s) available for carbostyril and Body Weight
Article | Year |
---|---|
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
Topics: Adult; Antidepressive Agents; Blood Glucose; Body Weight; Cholesterol; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Middle Aged; Quinolones; Thiophenes; Triglycerides | 2019 |
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult | 2018 |
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Risperidone; Treatment Outcome | 2014 |
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Double-Blind Method; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones | 2013 |
[Treatment of antipsychotic drug-induced phlegm dampness type amenorrhea by Wuji Powder and a small dose aripiprazole: a clinical study].
Topics: Aged; Amenorrhea; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Galactorrhea; Humans; Obesity; Piperazines; Quinolones; Waist-Hip Ratio | 2014 |
Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.
Topics: Aminophenols; Body Height; Body Weight; Child; Cystic Fibrosis; Double-Blind Method; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Quinolones; Treatment Outcome | 2017 |
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia | 2009 |
Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Headache; Humans; Lorazepam; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Young Adult | 2008 |
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Body Weight; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Quinolones; Treatment Outcome | 2008 |
Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Weight; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Tics; Tourette Syndrome; Treatment Outcome; Young Adult | 2009 |
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2011 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperazines; Quinolones; Time Factors; Treatment Outcome; Triazines; Valproic Acid | 2013 |
Disposition kinetics of enrofloxacin (Baytril 5%) in sheep and goats following intravenous and intramuscular injection using a microbiological assay.
Topics: Animals; Anti-Infective Agents; Body Weight; Enrofloxacin; Fluoroquinolones; Goats; Half-Life; Injections, Intramuscular; Injections, Intravenous; Kinetics; Logistic Models; Male; Microbial Sensitivity Tests; Quinolones; Sheep | 2002 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Patient Dropouts; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2005 |
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones | 2006 |
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2006 |
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides | 2006 |
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2007 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment | 2008 |
Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Tics; Tourette Syndrome; Treatment Outcome | 2008 |
Effect of water deprivation on the disposition kinetics of enrofloxacin in camels.
Topics: Absorption; Administration, Oral; Animals; Anti-Infective Agents; Biological Availability; Body Weight; Camelus; Eating; Enrofloxacin; Female; Fluoroquinolones; Half-Life; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Quinolones; Water Deprivation | 1995 |
Effectiveness of two fluoroquinolones for the treatment of chronic respiratory disease outbreak in broilers.
Topics: Animals; Anti-Infective Agents; Body Weight; Chickens; Chronic Disease; Disease Outbreaks; Enrofloxacin; Escherichia coli Infections; Fluoroquinolones; Mycoplasma Infections; Nicotinic Acids; Norfloxacin; Poultry Diseases; Probability; Quinolones; Respiratory Tract Infections; Survival Analysis | 1998 |
Therapy of difficult cases of canine pyoderma with marbofloxacin: a report of 39 dogs.
Topics: Animals; Anti-Infective Agents; Body Weight; Cellulitis; Dog Diseases; Dogs; Enzyme Inhibitors; Erythema; Female; Fluoroquinolones; Folliculitis; Follow-Up Studies; Male; Microbial Sensitivity Tests; Pruritus; Pyoderma; Quinolones; Recurrence; Skin Ulcer; Staphylococcal Infections; Treatment Outcome | 1999 |
The effect of organic acids on the control of post-weaning oedema disease of piglets.
Topics: Animal Feed; Animals; Anti-Infective Agents; Body Weight; Citric Acid; Dietary Supplements; Edema Disease of Swine; Enrofloxacin; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Intestine, Small; Lactic Acid; Male; Quinolones; Swine | 2001 |
57 other study(ies) available for carbostyril and Body Weight
Article | Year |
---|---|
Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.
Topics: Adult; Aminophenols; Benzodioxoles; Body Weight; Cardiometabolic Risk Factors; Chloride Channel Agonists; Cholesterol; Cystic Fibrosis; Humans; Indoles; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Retrospective Studies | 2022 |
Generation and Application of Inducible Chimeric RNA
Topics: 4-Nitroquinoline-1-oxide; Animals; Body Weight; Carcinogens; Disease Models, Animal; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Knock-In Techniques; Genotype; Mice; Mice, Inbred C57BL; Mouse Embryonic Stem Cells; Quinolones; RNA, Antisense; Tamoxifen | 2022 |
Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.
Topics: Adolescent; Adult; Age Factors; Aminophenols; Body Mass Index; Body Weight; Child; Chloride Channel Agonists; Chlorides; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Male; Quinolones; Sex Factors; Sweat; Young Adult | 2020 |
Nemonoxacin Has Immunoprotective Effects on Reducing Mortality in Lipopolysaccharide-Induced Mouse Sepsis Model.
Topics: Animals; Body Weight; Cytokines; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Immune System; Inflammation; Interleukin-10; Interleukin-6; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Myeloid Cells; Neutrophils; Phagocytosis; Quinolones; RAW 264.7 Cells; Sepsis; Spleen; Tumor Necrosis Factor-alpha | 2020 |
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
Topics: Animals; Blood Glucose; Body Weight; Down-Regulation; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Resistance; Intestine, Small; Liraglutide; Liver; Male; Metabolic Syndrome; Muscle, Skeletal; Pancreas; Quinolones; Rats; Signal Transduction; Thiophenes | 2021 |
Laquinimod treatment in the R6/2 mouse model.
Topics: Animals; Biomarkers; Body Weight; Brain-Derived Neurotrophic Factor; Cell Survival; Disease Models, Animal; Energy Metabolism; Fluorescent Antibody Technique; Gene Expression; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Neurons; PC12 Cells; Quinolones; Rats; Survival Rate | 2017 |
Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice.
Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Blood Proteins; Body Weight; Collagen Type I; Enzyme Inhibitors; Farnesyltranstransferase; Female; Kidney Failure, Chronic; Liver; Macrophages; Mevalonic Acid; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Prenylation; Quinolones; Random Allocation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tyrosine; Uremia; Vascular Calcification | 2013 |
Prenatal exposure of a novel antipsychotic aripiprazole: impact on maternal, fetal and postnatal body weight modulation in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Birth Weight; Body Weight; Eating; Female; Fetal Weight; Male; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar | 2014 |
Sweat chloride is not a useful marker of clinical response to Ivacaftor.
Topics: Aminophenols; Biomarkers; Body Height; Body Weight; Chlorides; Cohort Studies; Cystic Fibrosis; Forced Expiratory Flow Rates; Humans; Lung; Prospective Studies; Quinolones; Spirometry; Sweat | 2014 |
Ivacaftor. Uncertain harm-benefit balance.
Topics: Aminophenols; Body Weight; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Interactions; Forced Expiratory Volume; Humans; Quinolones; Randomized Controlled Trials as Topic; Uncertainty | 2013 |
Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Catenin; Body Weight; Cell Division; Cyclooxygenase 2; Dinoprostone; Female; Intestinal Absorption; Intestinal Mucosa; Jejunum; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Permeability; Proto-Oncogene Proteins c-myc; Quinolones; Random Allocation; Regeneration; RNA, Messenger; Tight Junctions | 2015 |
Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study.
Topics: Action Potentials; Animals; Body Weight; Brain; Dopamine; Male; Neurons; Neurotransmitter Agents; Norepinephrine; Psychotropic Drugs; Quinolones; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Serotonin; Thiophenes; Time Factors; Tissue Culture Techniques | 2015 |
Hypothalamic Phosphodiesterase 3B Pathway Mediates Anorectic and Body Weight-Reducing Effects of Insulin in Male Mice.
Topics: Animals; Body Weight; Cyclic Nucleotide Phosphodiesterases, Type 3; Eating; Gene Expression; Hypothalamus; Insulin; Leptin; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase Inhibitors; Phosphorylation; Pro-Opiomelanocortin; Proto-Oncogene Proteins c-akt; Quinolones; Signal Transduction; STAT3 Transcription Factor; Weight Loss | 2017 |
Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats.
Topics: Absorptiometry, Photon; Androgen Antagonists; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Estrogens; Female; Femur; Lumbar Vertebrae; Male; Orchiectomy; Organ Size; Osteocalcin; Ovariectomy; Pyrroles; Quinolones; Rats; Rats, Sprague-Dawley; Transcription, Genetic | 2009 |
Unusual weight fluctuation under corticosteroid and psychotropic treatment.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Aripiprazole; Body Weight; Cyclosporine; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Eating; Female; Humans; Mianserin; Paroxetine; Piperazines; Prednisolone; Quinolones; Sertraline; Takayasu Arteritis | 2008 |
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult | 2009 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats.
Topics: Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Aripiprazole; Astrocytes; Body Weight; Dose-Response Relationship, Drug; Gene Expression Regulation; Genetic Markers; In Situ Hybridization; Male; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Time Factors; Transcription, Genetic | 2009 |
Aripiprazole for the management of olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2009 |
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heart; Hormones; Humans; Japan; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Schizophrenia; Triglycerides | 2010 |
Trial of aripiprazole in the treatment of first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Weight; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2011 |
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia | 2011 |
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Female; Gene Expression Regulation; Hyperphagia; Lipid Metabolism; Lipogenesis; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Triglycerides; Weight Gain | 2012 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss | 2012 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
Comparative efficacy of enrofloxacin, oxytetracycline, and sulfadimethoxine for the control of morbidity and mortality caused by Escherichia coli in broiler chickens.
Topics: Air Sacs; Analysis of Variance; Animals; Anti-Bacterial Agents; Body Weight; Chickens; Enrofloxacin; Escherichia coli Infections; Fluoroquinolones; Oxytetracycline; Poultry Diseases; Quinolones; Sulfadimethoxine; Treatment Outcome | 2004 |
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.
Topics: Animals; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Olanzapine; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Rats, Wistar; Weight Gain | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis.
Topics: Administration, Oral; Animals; Behavior, Animal; Betamethasone Valerate; Body Weight; Dermatitis, Atopic; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Glucocorticoids; Immunosuppressive Agents; Male; Mice; Mice, Inbred Strains; Pruritus; Quinolones; Receptor, Cannabinoid, CB2; Severity of Illness Index; Skin; Tacrolimus | 2006 |
Aripiprazole in childhood and adolescence for Tourette syndrome.
Topics: Adolescent; Adolescent Behavior; Adult; Antipsychotic Agents; Aripiprazole; Attention; Body Weight; Child; Child Behavior; Cognition; Dose-Response Relationship, Drug; Humans; Male; Piperazines; Psychomotor Agitation; Quinolones; Tourette Syndrome; Treatment Outcome | 2006 |
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology | 2007 |
Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Dropouts; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones | 2007 |
High interstitial fluid pressure in rat tongue cancer is related to increased lymph vessel area, tumor size, invasiveness and decreased body weight.
Topics: 4-Nitroquinoline-1-oxide; Analysis of Variance; Animals; Body Weight; Carcinoma, Squamous Cell; Extracellular Fluid; Lymphatic Vessels; Male; Neoplasm Invasiveness; Pressure; Quinolones; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Tongue Neoplasms | 2008 |
Inhibition of aldose reductase in five tissues of the streptozotocin-diabetic rat.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Glucose; Kidney; Lens, Crystalline; Male; Organ Size; Quinolines; Quinolones; Rats; Rats, Inbred Strains; Retina; Sciatic Nerve; Seminal Vesicles; Sugar Alcohol Dehydrogenases | 1983 |
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Female; Hypertension; Male; Piperidines; Quinolones; Ramipril; Rats; Rats, Inbred SHR | 1995 |
Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Body Weight; Desoxycorticosterone; Hypertension; Male; Piperidines; Quinolones; Random Allocation; Rats; Rats, Wistar; Sodium Chloride | 1995 |
Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Diuresis; Glomerulosclerosis, Focal Segmental; Hypertension; Kidney; Male; Nephrectomy; Nephrosclerosis; Piperidines; Proteinuria; Quinolones; Rats; Rats, Inbred SHR | 1995 |
Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Capillary Resistance; Cardiac Output; Cardiac Pacing, Artificial; Diuresis; Dogs; Heart Failure; Hemodynamics; Kidney; Male; Natriuresis; Osmolar Concentration; Piperidines; Potassium; Quinolones; Renin; Sodium | 1994 |
Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin.
Topics: Animals; Animals, Newborn; Anti-Infective Agents; Body Weight; Cartilage, Articular; Ciprofloxacin; Female; Foot; Joint Diseases; Mice; Pipemidic Acid; Pregnancy; Quinolones | 1995 |
[A 13-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 5-week recovery test].
Topics: Administration, Oral; Alanine Transaminase; Animals; Anti-Infective Agents; Aspartate Aminotransferases; Beta-Globulins; Body Weight; Cartilage, Articular; Dioxolanes; Dogs; Dyskinesia, Drug-Induced; Female; Fluoroquinolones; gamma-Globulins; Male; Piperazines; Quinolones | 1996 |
One-month oral toxicity study of the new quinolone antibacterial agent (S)-10-[(S)-(8-amino-6-azaspiro[3,4]octan-6-yl)-9-fluoro-2,3-dihydro-3- methyl-7-oxo-7H-pyrido [1,2,3-de] [1,4] benzoxazine-6-carboxylic acid hemihydrate in rats and cynomolgus monkeys
Topics: Animals; Anti-Infective Agents; Blood Cell Count; Blood Chemical Analysis; Body Weight; Eating; Enzymes; Feces; Female; Fluoroquinolones; Macaca fascicularis; Male; Organ Size; Quinolones; Rats; Rats, Sprague-Dawley; Tissue Distribution | 1996 |
Molecular effects of M17055, furosemide and thiazide on cardiac hypertrophy of spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Diuretics; Electrolytes; Furosemide; Gene Expression; Heart Rate; Hypertension; Male; Myosin Heavy Chains; Oximes; Quinolones; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Trichlormethiazide | 1996 |
Effects of OPC-21268, a vasopressin V1-receptor antagonist, on expression of growth factors from glomeruli in spontaneously hypertensive rats.
Topics: Acetylglucosaminidase; Animals; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Growth Substances; Heart Rate; Hypertension; Kidney Glomerulus; Organ Size; Piperidines; Platelet-Derived Growth Factor; Polymerase Chain Reaction; Proliferating Cell Nuclear Antigen; Proteinuria; Quinolones; Random Allocation; Rats; Rats, Inbred SHR; RNA, Messenger; Sodium; Transforming Growth Factor beta; Urine | 1997 |
A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
Topics: Animals; Anti-Infective Agents; Blood Cells; Body Weight; Eating; Female; Fluoroquinolones; Humans; Infant, Newborn; Joint Diseases; Male; Organ Size; Piperazines; Quinolones; Rats; Survival Rate; Time Factors | 1999 |
Inhibition of spontaneous rat osteosarcoma lung metastasis by 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydroc arbostyril, a novel matrix metalloproteinase inhibitor.
Topics: Administration, Oral; Animals; Body Weight; Collagenases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme Precursors; Gelatinases; Lung Neoplasms; Male; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Molecular Weight; Neoplasm Transplantation; Organ Size; Osteosarcoma; Quinolones; Rats; Rats, Inbred F344; RNA, Messenger; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 1999 |
Experimental infections with Actinobacillus pleuropneumoniae in pigs--I. Comparison of five different parenteral antibiotic treatments.
Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Body Weight; Cephalosporins; Diterpenes; Enrofloxacin; Fluoroquinolones; Lung; Lung Diseases; Penicillins; Quinolones; Swine; Swine Diseases; Weight Gain | 1999 |
Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Area Under Curve; Body Weight; Cattle; Chromatography, High Pressure Liquid; Enrofloxacin; Fluoroquinolones; Half-Life; Injections, Intravenous; Least-Squares Analysis; Mice; Quinolones; Rabbits; Rats; Regression Analysis; Sheep; Ultrafiltration | 1999 |
Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Body Weight; Carcinogens; Cattle; Epithelium; Glutathione Transferase; Immunohistochemistry; Lactoferrin; Liver; Male; Mucous Membrane; NAD(P)H Dehydrogenase (Quinone); Organ Size; Ornithine Decarboxylase; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Quinolones; Rats; Rats, Inbred F344; Tongue; Tongue Neoplasms | 2000 |
Embryo lethality and teratogenicity of a new fluoroquinolone antibacterial DW-116 in rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anti-Infective Agents; Body Weight; Bone and Bones; Eating; Female; Fetal Death; Fluoroquinolones; Male; Maternal-Fetal Exchange; Piperazines; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Teratogens | 2000 |
Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Antidiuretic Hormone Receptor Antagonists; Blood Pressure; Body Weight; Hematocrit; Hypertension; Male; Organ Size; Osmolar Concentration; Piperidines; Quinolones; Rats; Rats, Sprague-Dawley; Urodynamics | 2000 |
A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Weight; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; DNA; DNA-Binding Proteins; Electrodes, Implanted; Enzyme Activation; Enzyme Inhibitors; Feeding Behavior; Hypothalamus; Injections, Intraventricular; Janus Kinase 2; Leptin; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinolones; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT3 Transcription Factor; Trans-Activators | 2002 |
Effect of enrofloxacin therapy on shipping fever pneumonia in feedlot cattle.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Blood Gas Analysis; Body Weight; Cattle; Enrofloxacin; Fluoroquinolones; Injections, Intramuscular; Male; Pasteurella Infections; Pasteurellosis, Pneumonic; Pneumonia; Quinolones | 1988 |
Reproductive studies of NY-198 in rats. I. Fertility study.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Body Weight; Drinking; Eating; Female; Fertility; Fluoroquinolones; Male; Quinolones; Rats; Salivation | 1988 |
Reproductive studies of NY-198 in rats. II. Teratology study.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Body Weight; Embryonic and Fetal Development; Female; Fetus; Fluoroquinolones; Male; Quinolones; Rats; Reproduction | 1988 |
Reproductive studies of NY-198 in rats. III. Perinatal and postnatal study.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Body Weight; Drinking; Eating; Embryonic and Fetal Development; Female; Fluoroquinolones; Lactation; Male; Pregnancy; Pregnancy, Animal; Quinolones; Rats; Reproduction | 1988 |